Immunovant Inc (IMVT)

$27.14

+0.95

(+3.63%)

Live

Insights on Immunovant Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 74.2% return, outperforming this stock by 42.5%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 242.2% return, outperforming this stock by 109.0%

Performance

  • $25.96
    $27.14
    $27.14
    downward going graph

    4.35%

    Downside

    Day's Volatility :4.35%

    Upside

    0.0%

    downward going graph
  • $18.16
    $45.58
    $27.14
    downward going graph

    33.09%

    Downside

    52 Weeks Volatility :60.16%

    Upside

    40.46%

    downward going graph

Returns

PeriodImmunovant IncSector (Health Care)Index (Russel 2000)
3 Months
-17.04%
0.3%
0.0%
6 Months
-27.61%
9.9%
0.0%
1 Year
31.74%
10.9%
0.0%
3 Years
132.8%
17.9%
-20.9%

Highlights

Market Capitalization
3.8B
Book Value
$4.24
Earnings Per Share (EPS)
-1.88
Wall Street Target Price
49.85
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-31.5%
Return On Equity TTM
-52.91%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-270.0M
Diluted Eps TTM
-1.88
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.77
EPS Estimate Next Year
-1.86
EPS Estimate Current Quarter
-0.43
EPS Estimate Next Quarter
-0.45

Analyst Recommendation

Buy
    95%Buy
    4%Hold
    0
    0%Sell
Based on 22 Wall street analysts offering stock ratings for Immunovant Inc(by analysts ranked 0 to 5 stars)
Based on 22 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
21
23
19
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 83.68%

Current $27.14
Target $49.85

Technicals Summary

Sell

Neutral

Buy

Immunovant Inc is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Immunovant Inc
Immunovant Inc
-15.16%
-27.61%
31.74%
132.8%
163.22%
Moderna, Inc.
Moderna, Inc.
-5.49%
54.62%
7.28%
-36.0%
777.93%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
5.25%
23.44%
33.01%
94.49%
224.24%
Novo Nordisk A/s
Novo Nordisk A/s
5.94%
38.98%
74.18%
240.71%
450.86%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
4.8%
16.75%
36.36%
148.95%
156.51%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Immunovant Inc
Immunovant Inc
NA
NA
NA
-1.77
-0.53
-0.31
NA
4.24
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.2
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
30.68
30.68
1.46
44.13
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
49.23
49.23
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
30.3
30.3
0.53
17.09
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Immunovant Inc
Immunovant Inc
Buy
$3.8B
163.22%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$51.1B
777.93%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$114.5B
224.24%
30.68
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$629.2B
450.86%
49.23
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$120.6B
156.51%
30.3
39.46%

Institutional Holdings

  • FMR Inc

    5.24%
  • Vanguard Group Inc

    4.44%
  • BlackRock Inc

    3.07%
  • State Street Corporation

    2.49%
  • Perceptive Advisors LLC

    2.03%
  • Armistice Capital, LLC

    1.48%

Corporate Announcements

  • Immunovant Inc Earnings

    Immunovant Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

immunovant, inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. it develops imvt-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in phase iia clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of phase ii clinical trials for the treatment of warm autoimmune hemolytic anemia. the company is headquartered in new york, new york. immunovant, inc. is a subsidiary of roivant sciences ltd.

Organization
Immunovant Inc
Employees
207
CEO
Dr. Frank M. Torti M.B.A., M.D.
Industry
Finance

FAQs